Author Archive

BPC June 13 updates: KMPH issued CRL. MRNS and RVNC both fail Phase 3 trials + updates for ARGS ARIA FCSC MESO ONCE VICL

Jun 14, 2016 No Comments

Updates to the Company Pipeline Database for June 13, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ARGS 5.95 AGS-003 ADAPT Trial Metastatic renal cell carcinoma (mRCC) Phase 3 Third interim analysis June 2016. Overall survival analysis due 1H 2017 ARIA 8.20 Iclusig (ponatinib) – OPTIC-2L Cancer – second line […]

Read more

BPC June 9 updates: KMPH PDUFA delay. SPHS rockets 125% after hours following data release + updates for ALNY ARWR CDTX IRWD OTIC VRX

Jun 09, 2016 No Comments

Updates to the Company Pipeline Database for June 9, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALNY 65.41 ALN-TTRsc02 ATTR amyloidosis Phase 1 Phase 3 to be initiated 2017 assuming positive Phase 1 initial data due end of 2016 ARWR 5.99 ARC-521 Chronic Hepititis B (HBV) Phase 1/2 Phase […]

Read more

BPC June 8 updates: FCSC Phase 2 trial fail. TENX Levosimendan data due 4Q. TRVN Phase 3 Oliceridine data due 1Q + updates for ADXS SCYX TGTX

Jun 09, 2016 No Comments

Updates to the Company Pipeline Database for June 8, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADXS 9.01 Axalimogene filolisbac (FAWCETT) Anal cancer Phase 2 Phase 2 initiated June 2016 FCSC 1.26 azficel-T Chronic Dysphonia Phase 2 Phase 2 endpoints not met – June 2016 SCYX 4.11 SCY-078 Vulvovaginal […]

Read more

BPC June 7 updates: CYTR data delayed until July. CATB falls on disappointing data. CLCD Phase 3 data due 3Q + updates for ALDX CYTX IMUC RGLS SAGE ZGNX

Jun 08, 2016 No Comments

Updates to the Company Pipeline Database for June 7, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALDX 5.75 NS2 Sjögren-Larsson Syndrome (SLS) Phase 2 Phase 2 data due 3Q 2016 CATB 6.85 CAT-2054 Hypercholesterolemia Phase 2a Phase 2a did not meet primary endpoint – June 2016 CLCD 7.16 […]

Read more

BPC June 6 updates: DNAI OCUL plummet following data. ADMP issued CRL. MSTX delays Phase 3 Sickle cell disease data + updates for ADXS AEZS ARRY CARA GLYC IMMU ONTY

Jun 07, 2016 No Comments

Updates to the Company Pipeline Database for June 6, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ADMP 4.09 Epinephrine Pre-filled Syringe (PFS) Emergency treatment of anaphylaxis. CRL CRL issued March 27 2015. NDA resubmitted. CRL issued again June 6, 2016. Intends to submit more data 2H 2016 ADXS […]

Read more

BPC June 2 updates: AKAO CORT FWP MBRX MDVN SMMT

Jun 03, 2016 No Comments

Updates to the Company Pipeline Database for June 2, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AKAO 3.61 Plazomicin – EPIC trial Complicated urinary tract infections (cUTI) Phase 3 Phase 3 top-line results due 1Q 2017 CORT 6.25 Mifepristone in combination with eribulin Cancer – triple-negative breast cancer […]

Read more

BPC June 1 updates: AAAP receives FDA Appoval. DERM releases Phase 3 data +updates for ATNM CANF EYEG PTLA RGLS RPRX

Jun 02, 2016 No Comments

Updates to the Company Pipeline Database for June 1, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AAAP 29.46 Somakit-TATE Neuroendocrine tumor diagnosis Approved Approved June 1 2016 ATNM 2.01 Actimab-A Acute Myeloid Leukemia (AML) Phase 1/2 Phase 2 to be initiated 2H 2016 CANF 2.96 CF101 Rheumatoid arthritis […]

Read more

BPC May 31 updates: STEM plunges on termination of stem trial. LXRX and VRTX PDUFA dates set for November 30 and September 30. RDUS NDA accepted. BMRN discontinues DMD + updates for BVXV CBAY CDTX

May 31, 2016 No Comments

Updates to the Company Pipeline Database for May 31, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary BMRN 89.65 Kyndrisa Duchenne Muscular Dystrophy (DMD) CRL CRL issued January 14 2016. Development terminated BVXV 3.60 M-001 Universal flu vaccine Phase 2b Phase 2b enrolment commenced March 2016. Data are due […]

Read more

BPC May 26 updates: NERV triples on Phase 2 data. FDA Approval wins for TTNP VNDA. RETA IPO. FLXN NDA filing 4Q. SAGE data due July + IONS AVEO NDRM

May 26, 2016 No Comments

Updates to the Company Pipeline Database for May 26, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary AVEO 0.92 TIVO-3 – tivozanib Third line treatment of patients with renal cell cancer Phase 3 Phase 3 dosing commenced May 2016. Data due 1Q 2018 FLXN 17.23 Zilretta – FX006 Osteoarthritis […]

Read more

BPC May 25 updates: SRPT PDUFA date DELAY + updates for ALDR CYTX DMPI NVAX RLYP SGEN

May 25, 2016 No Comments

Updates to the Company Pipeline Database for May 25, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary ALDR 27.74 ALD403 Chronic Migraine Phase 2b Phase 2b data released March 2016 met primary and secondary endpoints. 24 week data due 3Q 2016 CYTX 3.03 ECCS-50 Scleroderma Phase 3 Pivotal trial […]

Read more

BPC May 24 updates: CTIX release Phase 2 data + XBIT

May 24, 2016 No Comments

Updates to the Company Pipeline Database for May 24, 2016, are as follows. Refer to the FDA Calendar for upcoming catalysts: Ticker Price Drug Indication Stage Summary CTIX 1.59 Cellceutix Placque psoriasis Phase 2 Phase 2 top line data released May 2016 XBIT 2.44 Xilonix Colorectal cancer Phase 3 Phase 3 prelim data to be presented July 2 2016 […]

Read more